The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. (Q49352712)

20 February 2018

title

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. (English)

1 reference

20 February 2018

3

Ursula A Matulonis

1 reference

20 February 2018

author name string

Kathleen N Moore

series ordinal

1

1 reference

20 February 2018

Mansoor Raza Mirza

series ordinal

2

1 reference

20 February 2018

language of work or name

English

0 references

publication date

31 January 2018

1 reference

20 February 2018

published in

Gynecologic Oncology

1 reference

20 February 2018

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Robot-assisted versus conventional laparoscopic surgery for endometrial cancer staging: A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Guidelines for the Management of Hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Cancer-Related Fatigue, Version 2.2015.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

Effect of exercise on cancer-related fatigue: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2018.01.011

10.1016/J.YGYNO.2018.01.011

7 January 2021

Identifiers

DOI

1 reference

20 February 2018

1 reference

20 February 2018